Polydeoxyribonucleotides from bovine lung or other mammalian organs with molecular weight between 15,000 and 30,000.
Treatment of hepatic veno-occlusive disease
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AX Other antithrombotic agents
B01AX01 Defibrotide
D07423 Defibrotide sodium (JAN/USAN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
391 Liver disease agents
3919 Others
D07423 Defibrotide sodium (JAN/USAN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D07423
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D07423
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D07423
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D07423
